Muscle Growth & Performance Peptides

Understanding Peptides for Muscle Growth

Peptides for muscle growth are bioactive peptides that engage the growth hormone (GH) and insulin-like growth factor 1 (IGF-1) axis at different levels. Rather than acting as direct anabolic hormones, most either stimulate endogenous GH release or engage downstream signaling associated with cellular growth, tissue repair, and muscle protein synthesis.

Most compounds in this category fall into three functional groups. Growth hormone-releasing hormone (GHRH) analogs such as CJC-1295, Sermorelin, and Tesamorelin act on pituitary GHRH receptors. Growth hormone secretagogues such as Ipamorelin engage the ghrelin receptor (GHS-R1a) through a complementary pathway. IGF-1 and its analogs act farther downstream, binding IGF-1 receptors in skeletal muscle and other tissues. Increases in circulating GH or IGF-1 seen in early studies should not be equated with clinically meaningful hypertrophy or athletic performance benefits.

Types of Peptides for Muscle Growth

CJC-1295

CJC-1295 is a synthetic GHRH analog. The DAC-modified form binds albumin, prolongs systemic exposure, and extends GH-axis stimulation. In a small clinical study of healthy adults, single subcutaneous doses produced sustained, dose-dependent increases in circulating GH and IGF-1.[1] These findings demonstrate pharmacodynamic activity at the GH axis. They do not establish improvements in muscle size, strength, muscle protein synthesis, athletic performance, or post-exercise recovery.

Its prolonged exposure profile allows investigators to study extended GH-axis stimulation and endocrine responses over longer observation windows than shorter-acting analogs offer. Evidence for clinically meaningful body composition changes remains limited and should not be inferred from hormone increases alone.

IGF-1

Insulin-like growth factor 1 (IGF-1) sits downstream in the GH/IGF-1 axis and binds IGF-1 receptors in skeletal muscle and other tissues. Recombinant mecasermin (INCRELEX) is FDA-approved for growth failure in pediatric patients aged 2 years and older with severe primary IGF-1 deficiency, or with GH gene deletion and neutralizing antibodies to GH.[5] That approval does not extend to research-grade IGF-1 analogs, including IGF-1 LR3 and other modified forms, which remain investigational compounds without approved human indications.

Within laboratory models, IGF-1 activates intracellular signaling associated with protein synthesis and muscle-cell responses. Pathway activity in experimental systems does not by itself establish a clinically meaningful increase in human muscle mass.

Ipamorelin

Ipamorelin is a pentapeptide GH secretagogue that activates the ghrelin receptor. Preclinical pharmacology described it as a relatively selective GH secretagogue, with less cortisol and prolactin stimulation than earlier GHRP compounds in the experimental models tested.[2] Its short-acting GH-secretagogue pharmacology makes it useful in laboratory studies of endocrine signaling.

Discussions of the best peptide stack for muscle growth often pair Ipamorelin with CJC-1295. The two compounds act on complementary pathways, but current human research on their combined use, particularly for muscle growth, strength, or athletic recovery, is limited. The pairing should not be described as an established or extensively validated research combination.

Sermorelin

Sermorelin is a synthetic 29-amino-acid fragment of GHRH that retains biological activity at the pituitary GHRH receptor.[7] Its short half-life produces a transient GH response, making it useful as a comparator in studies of GHRH-related endocrine signaling. Researchers have studied it primarily in relation to GHRH pharmacology, pituitary GH secretion, and historical pediatric growth-hormone indications.[7] Researchers evaluating injectable peptides for muscle growth sometimes include Sermorelin as a shorter-acting comparator to CJC-1295.

Sermorelin was previously marketed as Geref for selected pediatric growth-hormone-related indications, but the relevant products were withdrawn from the U.S. market in 2009. The FDA later determined that the withdrawal was not for reasons of safety or effectiveness.[8] No currently marketed FDA-approved sermorelin product is available in the United States, and Sermorelin should now be understood as a research compound rather than a currently available pharmaceutical.

Tesamorelin

Tesamorelin is a stabilized GHRH analog engineered to resist enzymatic degradation. It is FDA-approved as EGRIFTA SV® for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, and it is not approved for muscle hypertrophy or athletic enhancement.[5]

In a randomized, double-blind clinical trial involving 412 adults with HIV-associated abdominal fat accumulation, daily tesamorelin reduced visceral adipose tissue compared with placebo over 26 weeks.[3] These findings describe a specific metabolic and body-composition effect in a defined clinical population and do not establish tesamorelin as a muscle-growth or performance-enhancing compound.

Although its approved indication differs from muscle research, Tesamorelin continues to be investigated for metabolic health, visceral adiposity, insulin sensitivity, and its ability to improve body composition. These investigations help researchers understand how GH-axis modulation influences fat distribution and lean tissue preservation.

Researchers may also encounter Follistatin, which inhibits myostatin signaling, and members of the broader GHRP family such as Hexarelin. Together with endogenous human growth hormone, these compounds provide additional models for investigating skeletal muscle adaptation, endocrine regulation, and anabolic signaling.

How the GH/IGF-1 Pathway Is Studied

Compounds in this class act at distinct points within the GH/IGF-1 signaling cascade. The magnitude and duration of the response depend on the compound, formulation, dose, and study conditions.

GHRH analogs activate GHRH receptors in the anterior pituitary and can stimulate GH secretion, which may increase hepatic and peripheral IGF-1 production. Pharmacologic stimulation of this pathway does not necessarily reproduce normal physiology, and sustained elevations in GH or IGF-1 can still alter endogenous feedback.

Ipamorelin activates the GHS-R1a receptor and, in preclinical work, showed relative selectivity for GH release with limited cortisol or prolactin stimulation compared with earlier GHRP compounds.[2] That selectivity supports laboratory studies of GH-secretagogue pharmacology and endocrine signaling, but does not itself demonstrate improvements in muscle growth, exercise recovery, or athletic performance.

Insulin-like growth factor 1 (IGF-1) sits downstream in the GH/IGF-1 axis and binds IGF-1 receptors in skeletal muscle and other tissues. Pathway activity in experimental systems should not be equated with proven increases in human muscle mass, strength, endurance, recovery, or lean-mass retention.

Research Applications in Muscle and Body-Composition Studies

Research involving these compounds focuses primarily on GH/IGF-1 signaling, endocrine responses, lean-tissue and body-composition endpoints, muscle homeostasis, tissue remodeling, and selected recovery-related measures. Investigators may also compare GHRH analogs, GH secretagogues, and IGF-1-related compounds to determine how signaling at different points of the endocrine pathway changes experimental outcomes.

Some studies additionally examine anti-catabolic responses associated with aging or disuse, muscle protein synthesis pathways, and recovery following exercise. However, measurable changes in GH or IGF-1 should not be interpreted automatically as evidence of clinically meaningful hypertrophy, increased strength, or improved athletic performance.

Current human evidence supports endocrine and pharmacodynamic measurements more strongly than claims of meaningful muscle-growth or performance improvement. Research protocols therefore distinguish mechanistic activity from demonstrated functional outcomes.

Athletic Performance, Recovery, and WADA Considerations

CJC-1295, Ipamorelin, IGF-1, and Tesamorelin appear in different endocrine, metabolic, developmental, and experimental tissue models. Direct evidence for improvements in athletic performance, strength, hypertrophy, endurance, or post-exercise recovery remains limited and differs substantially among compounds.

Performance-oriented research therefore tends to examine measurable endpoints such as endocrine responses, muscle-related biomarkers, body composition, and recovery kinetics rather than assuming a direct improvement in competitive performance. Consumer or commercial descriptions of these compounds should be distinguished from outcomes demonstrated in controlled studies.

Under the 2026 WADA Prohibited List, CJC-1295, sermorelin, and tesamorelin are listed as prohibited GHRH analogs, while Ipamorelin is listed as a prohibited GH secretagogue under section S2.2.4.[6] IGF-1 and related growth factors are addressed separately within the S2 prohibited-substances framework.[6] These substances are prohibited at all times for athletes subject to the World Anti-Doping Code, unless a valid therapeutic-use exemption or other applicable exception applies. Competitive-sport status depends on the specific substance, the applicable prohibited-list provision, and the athlete’s governing rules.

Regulatory Status & Approval Pathway

FDA status is compound-specific, and the U.S. Food and Drug Administration has not approved any product in this category for muscle hypertrophy or athletic enhancement. Compound-specific FDA records should be reviewed when evaluating regulatory status and research relevance. The current U.S. regulatory status of the individual compounds is as follows:

• Tesamorelin (EGRIFTA SV) is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.[4]
• Mecasermin (INCRELEX) is FDA-approved for growth failure in pediatric patients aged 2 years and older with severe primary IGF-1 deficiency, or certain GH-related conditions specified in the prescribing information.[5]
• Sermorelin was previously marketed as Geref for selected pediatric indications; the relevant approvals were later withdrawn, and no FDA-approved sermorelin product is currently marketed in the United States.[8]
• CJC-1295, Ipamorelin, Follistatin, Hexarelin, and most other GHRP compounds are not FDA-approved and are generally supplied for laboratory research only.

FDA approval for one indication does not extend to different uses. A licensed professional’s status alone does not authorize administration of an unapproved research product to patients, and procurement, importation, storage, and use must comply with applicable federal, state, and local requirements.

Safety Profile & Tolerability

Safety profiles differ by compound, dose, study population, and study duration, and should not be assumed uniform across the peptide class. Potential risks and side effects need to be weighed against the specific product and its evidence base.

Published human data on CJC-1295 reported sustained increases in GH and IGF-1 with generally favorable short-term tolerability across the study period,[1] but that study was not designed to evaluate long-term safety or muscle outcomes. Preclinical work observed ipamorelin’s relative selectivity for GH release, with limited cortisol or prolactin stimulation compared with earlier GHRP compounds [2], but this does not establish safety in extended human use.

Approved product labels give a more concrete picture within their approved populations. Tesamorelin prescribing information discusses glucose intolerance, fluid retention, hypersensitivity reactions, and monitoring requirements in the HIV-associated lipodystrophy population.[4] Those findings should not be extrapolated directly to healthy athletes or muscle-growth research. Mecasermin’s label identifies severe hypoglycemia, including hypoglycemic seizures, as an important risk and specifies dosing timing relative to meals.[5]

Safety cannot be generalized across the class and depends on the individual compound, dose, study population, duration, and available evidence. Identifying legal peptides for muscle growth also depends on jurisdiction and the specific compound.

Protocol and Stacking Considerations

Because endogenous GH release is regulated through multiple physiological pathways, laboratory protocols sometimes examine combinations of GH-releasing compounds. CJC-1295 and Ipamorelin are sometimes evaluated together because they influence complementary GH-regulating pathways.

Evidence for the combination remains limited, especially for muscle growth, strength, or athletic recovery, and it should not be described as an established or widely validated research stack. These compounds stimulate endogenous GH release rather than directly replacing GH, but pharmacologic stimulation can still alter normal endocrine feedback and does not necessarily reproduce normal physiology. Protocol variables include dosing interval, cycle length, endocrine biomarker selection, and body-composition endpoints.

Administration Technique

Subcutaneous administration has been used in human studies of CJC-1295[1] and is the administration route specified for approved tesamorelin[4] and mecasermin[5] products. Route, absorption, stability, storage, and handling requirements are compound-specific and must be drawn from validated research protocols or approved product documentation.

Research-grade materials may lack validated human-use handling instructions, and a route used in a study does not authorize clinical administration of an unapproved product. Refrigeration and cold-chain handling are not universally required for every peptide product either. Requirements depend on the compound’s stability data and the manufacturer’s storage specifications.

Alternative Options to Muscle Growth Peptides

Related research areas include:

• Metabolic peptides
• Tissue repair peptides
• Collagen-derived peptides
• Plant-based bioactive peptides

Each intersects with muscle growth and recovery peptides in different ways. Collagen-derived peptides are generally studied in nutritional rather than injectable research contexts. Plant-based bioactive peptides are also primarily investigated in dietary and nutritional models.

Sourcing and Distribution of Muscle-Growth Peptides

Distribution depends on the regulatory status of the individual compound. Approved products such as Tesamorelin and Mecasermin move through regulated pharmaceutical channels for their labeled indications, while investigational compounds used in laboratory research require documentation supporting identity, quality, and traceability.

Institutions sourcing muscle-growth and performance research peptides should review LOT-specific identity and purity data, assay methodology, manufacturer information, storage specifications, and shipping records appropriate to the compound. Documentation should correspond to the individual consignment rather than being reused across unrelated batches.

Shipping and storage requirements are compound-specific. Controlled temperatures should be used where supported by validated stability specifications rather than assumed to apply uniformly across every peptide.

Regulatory requirements for purchasing research peptides also differ by jurisdiction. Research-use materials should not be treated as clinically approved products merely because they are obtained by a licensed healthcare professional.

Looking to buy peptides for muscle growth online? Get in touch with our client support specialists at Medica Depot for further guidance.

Frequently Asked Questions

Does an increase in GH or IGF-1 prove that a peptide increases muscle growth?

No. A measurable endocrine response does not by itself establish clinically meaningful gains in muscle mass, strength, recovery, or athletic performance.

How do GHRH analogs differ from growth-hormone secretagogues?

CJC-1295, Sermorelin, and Tesamorelin act through pituitary GHRH receptors, while Ipamorelin activates the ghrelin receptor GHS-R1a. Both can influence GH signaling through different pathways.

Why are CJC-1295 and Ipamorelin often discussed together?

They act on complementary GH-regulating pathways. However, human evidence for the combination specifically improving muscle growth, strength, or athletic recovery remains limited.

Are any of these peptides FDA-approved specifically for muscle growth?

No. Tesamorelin and mecasermin have approved indications in other clinical settings, but those approvals do not extend to muscle hypertrophy or athletic enhancement.

How does WADA status differ from research status?

A compound may be studied in an authorized research setting while still being prohibited for athletes subject to the World Anti-Doping Code. Several GH-related compounds in this group are covered by the WADA Prohibited List.

Can muscle-growth peptides be treated as one safety class?

No. Safety findings depend on the individual compound, dose, population, exposure period, and available human evidence.

Where can licensed clinics order authentic peptides for muscle growth?

Licensed clinics should source investigational research peptides from suppliers that provide complete quality documentation, verifiable batch data, and controlled shipping. At Medica Depot, our client support specialists can share sourcing guidance and documentation appropriate for qualified institutions and licensed practitioners.

Disclaimer

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.

Citations and Resources

[1] Teichman, Sam L et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” The Journal of clinical endocrinology and metabolism vol. 91,3 (2006): 799-805. doi:10.1210/jc.2005-1536

[2] Raun, K et al. “Ipamorelin, the first selective growth hormone secretagogue.” European journal of endocrinology vol. 139,5 (1998): 552-61. doi:10.1530/eje.0.1390552

[3] Falutz, Julian et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” The New England journal of medicine vol. 357,23 (2007): 2359-70. doi:10.1056/NEJMoa072375

[4] National Library of Medicine. “EGRIFTA SV® (Tesamorelin) Kit: Prescribing Information.” DailyMed, updated 29 July 2026, dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224.

[5] National Library of Medicine. “INCRELEX® (Mecasermin) Injection: Prescribing Information.” DailyMed, updated 18 May 2026, dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce.

[6] World Anti-Doping Agency. “The Prohibited List.” World Anti-Doping Agency, www.wada-ama.org/en/prohibited-list.

[7] Prakash, A, and K L Goa. “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.” BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 12,2 (1999): 139-57. doi:10.2165/00063030-199912020-00007

[8] U.S. Food and Drug Administration. “Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness.” Federal Register, vol. 78, no. 42, 4 Mar. 2013, pp. 14095–14096, public-inspection.federalregister.gov/2013-04827.pdf.